Abstract
Management of hypertension has evolved steadily through 25 years of major clinical trials results modifying both the definition of hypertension and clinical management strategies. Trials experience in heart failure is much less extensive given the far smaller therapeutic market and traditionally often followed on the establishment of an agent or class of therapy in hypertension. Separate product profile development in heart failure is rare. Large outcome trials in heart failure are markedly smaller than those in hypertension and have tended to be confined to the last 15 years or so. There are clear examples of agents developed and successful in clinical use in both conditions but more recently the divergence of trials results in the two conditions has shown that comparable efficacy is no longer something which can be taken for granted. This review considers the past successes and more recent contrasts which have emerged in these traditional areas of pharmacological development.
Keywords: hypertension, heart failure, case linkage, neurohormonal suppression, arterial pressure, risk/benefit ratio
Current Pharmaceutical Design
Title: Hypertension to Heart Failure: New Developmental Strategies do not Cross a Clinical and Therapeutic Divide
Volume: 9 Issue: 21
Author(s): Robert J. MacFadyen, Gregory Y.H. Lip and Russell Davis
Affiliation:
Keywords: hypertension, heart failure, case linkage, neurohormonal suppression, arterial pressure, risk/benefit ratio
Abstract: Management of hypertension has evolved steadily through 25 years of major clinical trials results modifying both the definition of hypertension and clinical management strategies. Trials experience in heart failure is much less extensive given the far smaller therapeutic market and traditionally often followed on the establishment of an agent or class of therapy in hypertension. Separate product profile development in heart failure is rare. Large outcome trials in heart failure are markedly smaller than those in hypertension and have tended to be confined to the last 15 years or so. There are clear examples of agents developed and successful in clinical use in both conditions but more recently the divergence of trials results in the two conditions has shown that comparable efficacy is no longer something which can be taken for granted. This review considers the past successes and more recent contrasts which have emerged in these traditional areas of pharmacological development.
Export Options
About this article
Cite this article as:
MacFadyen J. Robert, Lip Y.H. Gregory and Davis Russell, Hypertension to Heart Failure: New Developmental Strategies do not Cross a Clinical and Therapeutic Divide, Current Pharmaceutical Design 2003; 9 (21) . https://dx.doi.org/10.2174/1381612033454504
DOI https://dx.doi.org/10.2174/1381612033454504 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Review on Bosentan, A Dual Endothelin Receptor Antagonist for the Treatment of Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery Propofol: Therapeutic Indications and Side-Effects
Current Pharmaceutical Design Recent Advances in Small Animal Cardiac Magnetic Resonance Imaging
Current Cardiology Reviews Apelin/Apelin Receptor System: Molecular Characteristics, Physiological Roles, and Prospects as a Target for Disease Prevention and Pharmacotherapy
Current Molecular Pharmacology Extracellular Matrix and Aberrant Signaling in Lung Carcinoma: Role of Fibronectin in the Control of Human Lung Carcinoma Cell Growth,Apoptosis and Resistance to Therapy
Current Signal Transduction Therapy Vascular Pathology from Smoking: Look at the Microcirculation!
Current Vascular Pharmacology Fluorescent Cisplatin Analogues and Cytotoxic Activity
Current Medicinal Chemistry Mitochondrial-Targeted Plastoquinone Derivatives. Effect on Senescence and Acute Age-Related Pathologies
Current Drug Targets Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists
Current Medicinal Chemistry New Analytical Tools for Studying Autoimmune Diseases
Current Pharmaceutical Design Antihypertensive Treatments in Patients Affected by Aortic Valve Stenosis
Current Pharmaceutical Design Old and New Drugs for Treatment of Advanced Heart Failure
Current Pharmaceutical Design Redox Homeostasis and Epigenetics in Non-alcoholic Fatty Liver Disease (NAFLD)
Current Pharmaceutical Design A Review of Intracoronary Abciximab in Percutaneous Coronary Interventions- where are we now and where do we go from here?
Recent Patents on Cardiovascular Drug Discovery The Role of Antithrombotic Therapy in Heart Failure
Current Pharmaceutical Design Prodrug Strategies for Antihypertensives
Current Topics in Medicinal Chemistry Non-Classical Structures Among Current Platinum Complexes with Potential as Antitumor Drugs
Current Topics in Medicinal Chemistry Evaluation of Cardiac Scan in Diagnosing Coronary-artery Disease
Current Medical Imaging microRNA Biogenesis Pathway as a Therapeutic Target for Human Disease and Cancer
Current Pharmaceutical Design Patient Education and Telemedicine in COPD
Current Respiratory Medicine Reviews